Accordingly, the present in vitro study aims to investigate the role of MAPF-induced endothelial EGFR expression and the efficacy of combined VEGF blockade with bevacizumab and gefitinib to suppress MAPF-induced angiogenesis in patients with lung cancer harboring mutant or wild-type EGFR using HUVECs. Here, EGFR is linked to lung carcinoma.